Aprea Therapeutics, Inc. (APRE)
APRE moved a median of -0.04% 30 minutes after news, and -1.53% by the close. How APRE actually reacts to news — the realized, point-in-time move the market made, measured across 221 labeled events over the last three years with zero look-ahead.
APRE’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 25% | 183 |
| 30-min | -0.04% | 41% | 203 |
| 60-min | -0.54% | 39% | 213 |
| to close | -1.53% | 35% | 218 |
| Middle 50% of APRE reactions | -3.33% to +1.13% |
|---|---|
| Median reaction (30-min) | -0.04% |
| Measured reactions | 221 |
Half of all Aprea Therapeutics, Inc. news events land between -3.33% and +1.13% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when APRE moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to APRE's baseline. Nothing else.
Recent APRE events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Aprea Therapeutics to Host Pre-ESMO Virtual Panel on the State of WEE1 Inhibition in Precision Oncology | Press release | GlobeNewswire | -1.25% | -11.22% | |
| Aprea Therapeutics to Present at October Conferences | Press release | GlobeNewswire | -3.78% | -1.52% | |
| Aprea Therapeutics to Present Updated Interim Phase 1 Data on WEE1 Inhibitor APR-1051 in an Oral Presentation at 38th EORTC-NCI-AACR Symposium | Press release | GlobeNewswire | -0.36% | -3.63% | |
| Aprea Therapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference | Press release | GlobeNewswire | +2.19% | +1.11% | |
| Aprea Therapeutics Announces Expansion of Intellectual Property Portfolio for Precision Oncology Programs | Press release | GlobeNewswire | -1.69% | -4.71% | |
| Form 8-K Aprea Therapeutics, Inc. For: Aug 28 | SEC filing · Form 8-K | SEC EDGAR | -1.69% | -4.71% | |
| Aprea Therapeutics Announces Second Quarter 2026 Financial Results | Press release | GlobeNewswire | -10.37% | -12.44% | |
| Form 10-Q Aprea Therapeutics, Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -10.37% | -12.44% | |
| Form 8-K Aprea Therapeutics, Inc. For: Aug 12 | SEC filing · Form 8-K | SEC EDGAR | -10.37% | -12.44% | |
| Aprea Therapeutics Provides ACESOT-1051 Program Update for WEE1 Inhibitor APR-1051: Accelerating and Expanding Enrollment. Clinical Data Presentation Planned for Q4 2026 | Press release | GlobeNewswire | — | +5.41% | |
| Form 8-K Aprea Therapeutics, Inc. For: Jul 23 | SEC filing · Form 8-K | SEC EDGAR | +7.37% | -2.92% | |
| Form 8-K Aprea Therapeutics, Inc. For: Jun 16 | SEC filing · Form 8-K | SEC EDGAR | -0.89% | -9.49% | |
| Aprea Therapeutics Presents Updated Phase 1 Data on WEE1 Inhibitor APR-1051 at ASCO 2026, Demonstrating Early Monotherapy Activity and Manageable Tolerability in Advanced Solid Tumors | Press release | GlobeNewswire | -1.61% | -2.87% | |
| Aprea Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update | Press release | GlobeNewswire | — | -9.13% | |
| Form 10-Q Aprea Therapeutics, Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | — | -9.13% | |
| Form 8-K Aprea Therapeutics, Inc. For: May 13 | SEC filing · Form 8-K | SEC EDGAR | — | -9.13% | |
| Form ARS Aprea Therapeutics, Inc. For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -0.63% | -1.19% | |
| Form DEF 14A Aprea Therapeutics, Inc. For: Jun 16 | SEC filing · Form DEF | SEC EDGAR | -0.63% | -1.19% | |
| Form DEFA14A Aprea Therapeutics, Inc. | SEC filing · Form DEFA14A | SEC EDGAR | -0.63% | -1.19% | |
| Form EFFECT Aprea Therapeutics, Inc. | SEC filing · Form EFFECT | SEC EDGAR | -0.63% | -1.19% | |
| CatalYm Appoints Christian S. Schade as Chairman of the Board of Directors | Press release | Business Wire | +0.06% | -1.54% | |
| Form S-3 Aprea Therapeutics, Inc. | SEC filing · Form S-3 | SEC EDGAR | +0.17% | -6.92% | |
| Aprea Therapeutics to Provide Clinical Update on ACESOT-1051 Phase 1 Trial Evaluating WEE1 Inhibitor, APR-1051, at ASCO 2026 Annual Meeting | Press release | GlobeNewswire | +0.16% | -8.90% | |
| Form PRE 14A Aprea Therapeutics, Inc. For: Jun 16 | SEC filing · Form PRE | SEC EDGAR | -1.96% | -3.82% | |
| Frazier Life Sciences Appoints Christian Schade as Senior Advisor | Press release | Business Wire | -1.28% | -4.48% | |
| Aprea Therapeutics Announces Closing of Oversubscribed $30 Million Private Placement | Press release | GlobeNewswire | -1.48% | -5.02% | |
| Form 8-K Aprea Therapeutics, Inc. For: Apr 01 | SEC filing · Form 8-K | SEC EDGAR | -1.48% | -5.02% | |
| Aprea Therapeutics Announces Oversubscribed $30 Million Private Placement | Press release | GlobeNewswire | -6.97% | -0.36% | |
| Aprea Therapeutics Highlights Positive Emerging Clinical Activity for WEE1 Inhibitor, APR-1051, with a Confirmed Partial Response in the Ongoing Phase 1 ACESOT-1051 Trial | Press release | GlobeNewswire | -6.97% | -0.36% | |
| Form 8-K Aprea Therapeutics, Inc. For: Mar 30 | SEC filing · Form 8-K | SEC EDGAR | -0.63% | +9.87% | |
| Form EFFECT Aprea Therapeutics, Inc. | SEC filing · Form EFFECT | SEC EDGAR | +0.00% | -0.17% | |
| Form S-3/A Aprea Therapeutics, Inc. | SEC filing · Form S-3 | SEC EDGAR | — | -6.27% | |
| Aprea Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update | Press release | GlobeNewswire | -7.91% | -9.99% | |
| Form 10-K Aprea Therapeutics, Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -7.91% | -9.99% | |
| Form 8-K Aprea Therapeutics, Inc. For: Mar 16 | SEC filing · Form 8-K | SEC EDGAR | -7.91% | -9.99% | |
| Form S-8 Aprea Therapeutics, Inc. | SEC filing · Form S-8 | SEC EDGAR | -2.22% | +2.92% | |
| Form S-3 Aprea Therapeutics, Inc. | SEC filing · Form S-3 | SEC EDGAR | -4.04% | -6.41% | |
| Aprea Therapeutics Announces Additional Positive Clinical Activity for WEE1 Inhibitor, APR-1051, Including Second Partial Response in Ongoing ACESOT-1051 Trial | Press release | GlobeNewswire | -0.65% | +3.19% | |
| Form 8-K Aprea Therapeutics, Inc. For: Feb 18 | SEC filing · Form 8-K | SEC EDGAR | -0.65% | +3.19% | |
| Aprea Therapeutics to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference | Press release | GlobeNewswire | -0.05% | -1.53% | |
| Aprea Therapeutics Strengthens Global Patent Portfolio in DNA Damage Response (DDR) Cancer Therapeutics, Paving Way for Pipeline Growth | Press release | GlobeNewswire | -0.30% | -7.68% | |
| Aprea Therapeutics Appoints Industry Veteran Eugene Kennedy, MD, as Chief Medical Advisor | Press release | GlobeNewswire | -1.31% | +0.00% | |
| Aprea Therapeutics Announces $5.6 Million Private Placement Priced At-The-Market Under Nasdaq Rules | Press release | GlobeNewswire | -15.25% | -22.37% | |
| Aprea Therapeutics Announces Early Clinical Proof-Of-Concept in the Ongoing ACESOT-1051 Dose-Escalation Trial Evaluating WEE1 Inhibitor APR-1051, Including Partial Response Observed on First Scan | Press release | GlobeNewswire | -15.25% | -22.37% | |
| Form 8-K Aprea Therapeutics, Inc. For: Jan 28 | SEC filing · Form 8-K | SEC EDGAR | +4.31% | +30.49% | |
| Form 8-K Aprea Therapeutics, Inc. For: Jan 23 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -2.73% | |
| Form 8-K Aprea Therapeutics, Inc. For: Jan 09 | SEC filing · Form 8-K | SEC EDGAR | +1.48% | -1.07% | |
| Form EFFECT Aprea Therapeutics, Inc. | SEC filing · Form EFFECT | SEC EDGAR | +0.00% | -3.26% | |
| Form D Aprea Therapeutics, Inc. | SEC filing · Form D | SEC EDGAR | -2.95% | -8.87% | |
| Form S-3 Aprea Therapeutics, Inc. | SEC filing · Form S-3 | SEC EDGAR | +3.28% | -1.01% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the APRE section they belong to.
Where else APRE is measured.
APRE earnings → · Analyst actions → · SEC filings →
Other Industrials names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Embraer S.A. (ERJ) | 222 | +0.13% | 59% |
| Triumph Group, Inc. (TGI) | 222 | 0.00% | 48% |
| LEGACY ACQUISTION CORP (LGC) | 221 | 0.00% | 16% |
| TOMI Environmental Solutions, Inc. (TOMZ) | 220 | 0.00% | 50% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Industrials names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Aprea Therapeutics, Inc.'s median reaction calculated?
Every labeled APRE news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 221 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 41% of APRE's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does APRE's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.